Dr. Ghassan Abou-Alfa of Memorial Sloan Kettering Cancer Center shares a recent abstract from ASCO GI, IMBRAVE-151, A Phase II, randomized, double-blind placebo-controlled study of atezolizumab with or without bevacizumab in combination
Dr. Ghassan Abou-Alfa of Memorial Sloan Kettering Cancer Center shares a recent abstract from ASCO GI, IMBRAVE-151, A Phase II, randomized, double-blind placebo-controlled study of atezolizumab with or without bevacizumab in combination
More
ASCO Direct™ Highlights Oncology conference held in Seattle to present and discuss the latest findings in cancer research and treatments The Binaytara Foundation held the ASCO Direct™ Highlights: 2022 Official Annual Meeting
More